Satellos Bioscience Inc.
MSLENASDAQHealthcareBiotechnology
Previous close
$10.01
−$0.175 · -1.72%
MSLE company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
35
Expensive
Momentum
80
Gaining
Sentiment
68
Bullish
Risk resilience
39
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteSatellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- CA
- CEO
- Frank Gleeson
- Listed since
- Aug 3, 2012
- Employees
- 18
Market position
Day range
Current $10.01
52-week range
Current $10.01
- Open
- $10.00
- Previous close
- $10.185
- Volume
- 22.06K
- 0.44× average
- Average volume
- 50.06K
- Average daily volume
- Market cap
- 12.9M USD
- Beta
- 1.17
- Market reference 1
- 50-day average
- $8.5797
- +16.67% above average
- 200-day average
- $7.9696
- +25.60% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -1.19M USD
- P/E (TTM)
- -5×
- P/B (TTM)
- 3.41×
- P/S (TTM)
- 0×
- EV / EBITDA
- 0.05×
- Earnings yield
- -288.83%
- Free cash flow yield
- -274.08%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -89.52%
- Return on assets
- -78.00%
- Return on invested capital
- -95.23%
Financial health
- Debt / equity
- 0×
- Current ratio
- 7.77×
- Altman Z-score
- -1.07
- Piotroski F-score
- 1 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 5.09K USD | 19.99K USD | 5.28K USD | 333.98K USD | 166.94K USD |
| Gross profit | −5.09K USD | −19.99K USD | −5.28K USD | −333.98K USD | −166.94K USD |
| Research and development | 18.43M USD | 13.66M USD | 6.65M USD | 3.7M USD | 1.9M USD |
| Selling, general, and administrative | 7.44M USD | 5.16M USD | 4.57M USD | 3.92M USD | 1.13M USD |
| Operating expenses | 26.46M USD | 19.38M USD | 11.66M USD | 8M USD | 4.72M USD |
| Interest income | 1.36M USD | 955.27K USD | 1M USD | 62.37K USD | 6.26K USD |
| Interest expense | — | — | 133.42K USD | — | 772.8K USD |
| Depreciation and amortization | 5K USD | 13.94K USD | 5.28K USD | 333.63K USD | 129.95K USD |
| Operating income | −26.46M USD | −19.38M USD | −11.66M USD | −8.34M USD | −4.89M USD |
| Net income | −24.87M USD | −19.58M USD | −11.98M USD | −11.21M USD | −12.16M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 9%
- 1 beat, 10 misses, 0 met estimates
- Average EPS surprise
- -51.52%
- 11 comparable reports
- Latest EPS result
- -0.56
- Estimate -0.51 · Miss by 9.73%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$19.67
96.50% upsideMSLE peers
Continue in GoAI
Research MSLEresearch.disclaimer